Patent · US Active

Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof

US9707211B2 · kind B2 · utility

4Cited by

14References

30Claims

0Family size

Assignee

Lycera Corporation · US

Inventors

Alexander R. Hurd · Ann Arbor, US
Clarke B. Taylor · Ann Arbor, US
Jian Wang · Newton, US
Peng Zhou · Suzhou, CN

Key dates

Filing date	Feb 4, 2016
Grant date	Jul 18, 2017
Priority date	—
Expiry date	Feb 4, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0053
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.